GINA update July 2023
https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS.pdf
For adults and adolescents, the preferred Step 3 treatment is the Track 1 regimen with low-dose ICS-formoterol as maintenance and reliever therapy (MART). This reduces the risk of severe exacerbations, with simiar or better symptom control, compared with maintenance treatment using a combination of an ICS and a long-acting beta2 agonist (LABA) as controller, plus as-needed SABA.
Other stap 3 options for adults and adolescents in Track 2, and in children, include maintenance ICS-LABA plus as-needed SABA or plus as-needed ICS-SABA (if available)
Consensus that we are not moving to GINA right now